Liver transplantation for acute-on-chronic liver failure

Tomescu, Dana; Popescu, Mihai; Biancofiore, Gianni

doi:10.1016/j.bpa.2019.12.001

Cited by 2 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the main treatment methods for liver failure include internal medicine treatment, artificial liver and liver transplantation, among which liver transplantation is the most effective treatment [ 18 ]. However, due to the lack of donor liver, the high cost of transplantation and the serious immune rejection after transplantation, its wide application is restricted [ 19 ]. Therefore, it is still an urgent clinical problem to find a new method for the effective treatment of liver failure.…”

Section: Discussionmentioning

confidence: 99%

The high level of IL-1β in the serum of ACLF patients induces increased IL-8 expression in hUC-MSCs and reduces the efficacy of hUC-MSCs in liver failure

Wang,

Tao

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

Background Stem cells play a therapeutic role mainly through immunoregulation. However, the immunomodulatory function of stem cells may be affected by inflammation-related factors in patients’ serum. Therefore, this study aims to investigate the possible mechanism by which acute-on-chronic liver failure (ACLF) patient serum influences the efficacy of hUC-MSCs. Methods The serum of surviving and dead ACLF patients was collected to culture hUC-MSCs in vitro, and the hUC-MSCs cultured in the serum of ACLF patients were used to treat acute liver failure (ALF) rats. The therapeutic effect on the rats was evaluated by a survival curve, the transaminase level and liver histopathology. The expression of cytokines in hUC-MSCs was detected by Q-PCR and ELISA. Results Serum pretreatment reduced the therapeutic effect of hUC-MSCs on ALF, especially pretreatment in the serum from dead ACLF patients. After hUC-MSCs were cultured in the serum of surviving or dead ACLF patients, the most differentially expressed factor was IL-8. Interfering with the expression of IL-8 in hUC-MSCs can improve the therapeutic effect of hUC-MSCs on ALF. The high level of IL-1β in the serum of dead ACLF patients causes the increased expression of IL-8 in hUC-MSCs through the activation of the NF-κB signaling pathway. Meanwhile, we found that the neutralizing IL-1β in serum from dead ACLF patients can improve the therapeutic effect of hUC-MSCs on ALF. Conclusion The high level of IL-1β in ACLF serum can promote the expression of IL-8 in hUC-MSCs through the NF-κB signaling pathway, thus reducing the effect of hUC-MSCs on ALF.

show abstract

Section: Discussionmentioning

confidence: 99%